Health · 1 sources covering this

STAT+: A journey to witness China’s biotech boom up close

Chinese-designed drugs now account for roughly half the global pipeline. STAT's Jason Mast traveled to Shanghai to get an up-close look at the competition that's making American's nervous.

Share:X WhatsApp Reddit Facebook LinkedIn Open ↗

Coverage spectrum

0 L · 1 C · 0 R

How 1 sources are covering this

STATCenter·2h ago
STAT+: A journey to witness China’s biotech boom up close
Chinese-designed drugs now account for roughly half the global pipeline. STAT's Jason Mast traveled to Shanghai to get an up-close look at the competition that's making American's nervous.
Read at STAT →

Embed this bias spectrum on your site

Paste this iframe wherever you'd like the widget to appear. Resizes responsively; no JS required.

<iframe
  src="https://statesidedaily.com/embed/cluster/1da3743703fc9ce4ee124e5ba1bffd51cfe2117b"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: A journey to witness China&#8217;s biotech boom up close"></iframe>

STAT+: A journey to witness China’s biotech boom up close

How 1 sources are covering this

STAT+: A journey to witness China’s biotech boom up close

More from Health

Mistrust in science and a juicy gene-editing lawsuit

As CDC redesigns annual health survey, it removes questions about disabilities

STAT+: MAHA goes corporate

STAT+: A major insurer on how it may replicate Medicare’s chronic-care experiment

Reader

Trust & legal

Across the network

How 1 sources are covering this

STAT+: A journey to witness China&#8217;s biotech boom up close

More from Health

Mistrust in science and a juicy gene-editing lawsuit

As CDC redesigns annual health survey, it removes questions about disabilities

STAT+: MAHA goes corporate

STAT+: A major insurer on how it may replicate Medicare&#8217;s chronic-care experiment

Reader

Trust & legal

Across the network

STAT+: A journey to witness China’s biotech boom up close

STAT+: A major insurer on how it may replicate Medicare’s chronic-care experiment